Another study involving both animal models and cell lines demonstrated that BMP9 ablation promotes liver steatosis, with the mechanism being that BMP9 treatment attenuates triglyceride accumulation by enhancing peroxisome proliferator-activated receptor α (PPARα) promoter activity through the activation of phosphorylated Smad (pSmad) [105]. The gene discussed is GDF2; the disease is fatty liver disease.